Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07700745

A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with self-reported eczema-prone skin. Participants will use the body wash once daily in place of their usual cleanser, followed by the Skin Recovery Cream, for 4 consecutive weeks.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult women or men aged 18-65 years.
  • Self-reported symptoms of eczema or eczema-prone skin (e.g., dryness, roughness, itching, irritation on the body).
  • Visible signs of eczema such as dryness, roughness, or irritation on at least one part of the body at the time of enrollment.
  • Willing to use Rejuvaskin Eczema Body Wash once daily as their primary body cleanser for 4 consecutive weeks.
  • Willing to use Rejuvaskin Skin Recovery Cream once daily after using the - Rejuvaskin body cleanser for 4 consecutive weeks.
  • Willing to maintain their current diet, skincare routine (aside from substitution of body wash and skin cream), and lifestyle habits for the study duration.
  • Willing and able to take standardized photographs of an affected body area at Baseline and Week 4 using a personal smartphone.
  • Able to read, understand, and complete questionnaires in English.
  • Resides in the United States with a valid shipping address.
  • Willing to provide informed consent and comply with all study procedures

Exclusion criteria

  • Known allergy or sensitivity to any ingredient in the study product.
  • Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Active, severe skin condition on the body requiring prescription topical or systemic treatment (e.g., active severe atopic dermatitis flare under medical care, active infection at intended application sites).
  • Currently using prescription topical corticosteroids, calcineurin inhibitors, or other prescription topical eczema treatments on the body, or initiation of such treatment planned during the study.
  • Currently participating in another clinical or skincare research study, or planning to enroll during this study's duration. (

Treatment and study plan

Rejuvaskin Eczema Body Wash

Dietary Supplement

Participants use Rejuvaskin Eczema Body Wash once daily during a shower or bath in place of their usual body cleanser, followed by application of Rejuvaskin Skin Recovery Cream, for 4 consecutive weeks.

Primary outcomes

  1. Change from Baseline in Self-Reported Skin Dryness

    Time frame: Baseline to Week 4

    Mean change in self-reported dryness measured via a structured self-report questionnaire administered through the Citruslabs platform

  2. Change from Baseline in Self-Reported Skin Roughness

    Time frame: Baseline to Week 4

    Mean change in self-reported roughness measured via a structured self-report questionnaire administered through the Citruslabs platform

  3. Change from Baseline in Self-Reported Skin Itch

    Time frame: Baseline to Week 4

    Mean change in self-reported itch measured via a structured self-report questionnaire administered through the Citruslabs platform

  4. Change from Baseline in Self-Reported Skin Irritation

    Time frame: Baseline to Week 4

    Mean change in self-reported irritation measured via a structured self-report questionnaire administered through the Citruslabs platform

  5. Change from Baseline in Self-Reported Skin Discomfort

    Time frame: Baseline to Week 4

    Mean change in self-reported discomfort measured via a structured self-report questionnaire administered through the Citruslabs platform

Secondary outcomes

  1. Change from Baseline in Self-Reported Skin Hydration

    Time frame: Baseline to Week 4

    Mean change in self-reported skin hydration measured via a 0-10 Numeric Rating Scale (NRS) self-report questionnaire

  2. Change from Baseline in Self-Reported Skin Comfort

    Time frame: Baseline to Week 4

    Mean change in self-reported skin hydration measured via a 0-10 Numeric Rating Scale (NRS) self-report questionnaire

  3. Expert Dermatologist-Graded Change in Erythema

    Time frame: Baseline and Week 4

    Independent expert dermatologist grading of change in erythema from standardized photographs of a designated affected body area

  4. Expert Dermatologist-Graded Change in Scaling

    Time frame: Baseline and Week 4

    Independent expert dermatologist grading of change in scaling from standardized photographs of a designated affected body area

Sponsors and collaborators

Lead sponsor

Rejuvaskin

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 14, 2026
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.